Claims for Patent: 8,440,610

Summary for Patent: 8,440,610

Title:	Mapkap kinase-2 as a specific target for blocking proliferation of P53-defective cells
Abstract:	The present invention relates to compounds and pharmaceutical compositions for treating cellular proliferative disorders, e.g., in patients having one or more p53-deficient cells, screening assays for identifying such compounds, and methods for treating such disorders.
Inventor(s):	Yaffe; Michael B. (West Roxbury, MA), Manke; Isaac A. (New York, NY), Reinhardt; Hans Christian (Cambridge, MA)
Assignee:	Massachusetts Institute of Technology (Cambridge, MA)
Application Number:	11/789,239
Patent Claims:	1. A method for treating a cellular proliferative disorder in a patient having a p53-deficient cell, said method comprising administering to the patient a peptide comprising the amino acid sequence LQRQLSI (SEQ ID NO: 16), wherein the peptide comprises no more than 50 amino acids, and wherein the peptide is capable of inhibiting an activity of a MAPKAP kinase-2 polypeptide. 2. The method of claim 1, wherein said patient has a tumor, and wherein said peptide is administered to said tumor. 3. The method of claim 2, wherein said peptide is administered to said tumor by direct injection. 4. The method of claim 2, wherein said administration results in a reduction in size of said tumor, in comparison to a control patient to whom said peptide is not administered. 5. The method of claim 1, wherein said administering induces increased sensitivity of said p53-deficient cell to a chemotherapeutic agent, in comparison to a p53-deficient control cell in a control patient to whom said peptide is not administered. 6. The method of claim 5, wherein said chemotherapeutic agent is selected from the group consisting of alemtuzumab, altretamine, aminoglutethimide, amsacrine, anastrozole, azacitidine, bleomycin, bicalutamide, busulfan, capecitabine, carboplatin, carmustine, celecoxib, chlorambucil, 2-chlorodeoxyadenosine, cisplatin, colchicine, cyclophosphamide, cytarabine, cytoxan, dacarbazine, dactinomycin, daunorubicin, docetaxel, doxorubicin, epirubicin, estramustine phosphate, etodolac, etoposide, exemestane, floxuridine, fludarabine, 5-fluorouracil, flutamide, formestane, gemcitabine, gentuzumab, goserelin, hexamethylmelamine, hydroxyurea, hypericin, ifosfamide, imatinib, interferon, irinotecan, letrozole, leuporelin, lomustine, mechlorethamine, melphalen, mercaptopurine, 6-mercaptopurine, methotrexate, mitomycin, mitotane, mitoxantrone, nilutamide, nocodazole, paclitaxel, pentostatin, procarbazine, raltitrexed, rituximab, rofecoxib, streptozocin, tamoxifen, temozolomide, teniposide, 6-thioguanine, topotecan, toremofine, trastuzumab, vinblastine, vincristine, vindesine, and vinorelbine. 7. The method of claim 5, wherein said administering alters a DNA damage-responsive cell cycle checkpoint of said p53-deficient cell in comparison to said control cell. 8. The method of claim 7, wherein said DNA damage-responsive cell cycle checkpoint is G.sub.1/S phase arrest. 9. The method of claim 8, wherein Cdc25a degradation in a p53-deficient cell is impaired in comparison to a p53-deficient control cell in a control patient. 10. The method of claim 7, wherein said DNA damage-responsive cell cycle checkpoint is G.sub.2/M phase arrest. 11. The method of claim 10, wherein the interaction between Cdc25b and a 14-3-3 protein is reduced in comparison to a p53-deficient control cell in a control patient. 12. The method of claim 7, wherein said cell cycle checkpoint alteration induces cell death. 13. The method of claim 12, wherein said cell death is by apoptosis. 14. The method of claim 13, wherein said apoptosis is at least partially dependent on caspase-3 activation.

Details for Patent 8,440,610

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2024-11-12
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2024-11-12
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2024-11-12
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2024-11-12
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	05/07/2001		2024-11-12
Genzyme Corporation	LEMTRADA	alemtuzumab	Injection	103948	11/14/2014		2024-11-12
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	10/12/2004		2024-11-12